Introduction
============

Colorectal cancer (CRC) is the third cancer in Europe with fatal outcome. Currently, therapy for locally advanced CRC relies on neoadjuvant chemo-radiotherapy (CRT) in some patients in order to increase the tumor-free resection margin ([@r1]). Inflammation within cancers might influence future behavior of malignant cells and blood vessels, as well as therapeutic response. Some serum biomarkers might give information on the level of systemic inflammation and determine the future course of disease in many cancer patients. Anemia, hemoglobinemia, thrombocytosis and elevated C-reactive protein (CRP) values are thought to be adverse prognostic factors in various malignancies ([@r2]). Recently, it has been reported that the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) might indicate patients that will respond poorly to treatments (neoadjuvant CRT) and who will have worse disease-free survival (DFS) and overall survival (OS) in many cancers such as small cell lung carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, and head and neck cancers. Systemic meta-analysis in CRC patients has shown that NLR has a prognostic value in terms of rational patient stratification for further treatment adjustment ([@r3]). As suggested by Kitayama *et al*. ([@r4]), tumor shrinkage is dependable on tumor cells and host characteristics, therefore, there is a possibility that a lymphocyte-mediated immune reaction might result in partial or total eradication of tumor cells. Therefore, lymphocyte count in the circulation may improve response to therapy in CRC patients. However, the role of NLR and PLR in CRC after CRT and before surgery is yet to be established.

Materials and Methods
=====================

Prior to this study, participants signed informed consent according to Helsinki II. Initially, 150 charts of patients having undergone neoadjuvant CRT followed by surgery at the Hospital for Tumors, Sestre milosrdnice University Hospital Centre in Zagreb, were retrieved. Of these, 71 patient charts that included data on all study parameters were analyzed for complete blood count, lymphocyte, leukocyte, neutrophil and platelet counts, hemoglobin, NLR and PLR. NLR was calculated by dividing absolute neutrophil count by absolute lymphocyte count. PLR was calculated by dividing absolute platelet count by absolute lymphocyte count. Primary tumors were staged by use of magnetic resonance imaging (MRI). All patients were irradiated and administered concurrent 5-fluorouracil-based chemotherapy. The mean radiation dose was 45 Gy (range 45-50.4 Gy) with daily fraction of 1.8. Gy. Radiation treatment was performed according to the institutional protocols. Pathological tumor staging of surgical specimen was performed in accordance with the 7^th^ Guidelines of the American Joint Committee on Cancer ([@r5]). The primary endpoint of the study was OS and DFS. OS was defined as the time from the date of surgery to death. DFS was defined as the time from the date of surgery to the date of tumor relapse (local recurrence and/or distant metastases) or death. The secondary endpoint was neoadjuvant chemoradiation response as measured by ypTNM staging. In the ypTNM staging system, good response was defined as ypT0 to 2 without lymph node metastases, and poor response was defined as ypT3 to 4 or with lymph node metastases. Statistical analysis included Mann-Whitney U test, Student's t-test, univariate and multivariate analysis. The level of significance was set at p\<0.05.

Results
=======

The results of Mann-Whitney U test and Student's t-test showed that neutrophil count (p=0.024), NLR (p=0.003) and PLR (p=0.007) correlated significantly with OS ([Table 1](#t1){ref-type="table"}). However, there was no significant correlation of age, leukocyte, lymphocyte and platelet counts, and hemoglobin values with OS. Furthermore, the same tests showed that leukocyte (p=0.04), neutrophil (p=0.0014) and platelet (p=0.006) counts, NLR (p=0.0006) and PLR (p=0.0015), as well as hemoglobin values (p=0.028) correlated significantly with DFS ([Table 2](#t2){ref-type="table"}). The results of univariate analysis showed that unlike PLR, NLR correlated with OS and DFS (p=0.0002); however, correlation of PLR and DFS almost reached significance (p=0.059). There was no correlation between patient age and gender, tumor stage and neoadjuvant CRT with OS and DFS ([Table 3](#t3){ref-type="table"}). The results of multivariate analysis showed that NLR (cut-off value 3.27) and advanced pathological TNM stage significantly correlated with DFS but not with OS ([Table 4](#t4){ref-type="table"}).

###### Age, complete blood count and overall survival in the study population

  Characteristic       Overall survival   p value        
  -------------------- ------------------ -------------- ---------
  Yes                  No                                
  Number of patients   63                 8              \-
  Age^a^ (yrs)         61 (36-79)         56.5 (34-79)   0.68
  Leukocytes^b^        8.16±1.94          9.04±3.42      0.27
  Neutrophils^b^       5.13±1.6           6.64±2.77      0.024\*
  Lymphocytes^b^       2.03±0.55          1.7±0.7        0.138
  Platelets^b^         310.7±97.58        397.12±239.9   0.059
  NLR^b^               2.76±1.27          4.36±2.18      0.003\*
  PLR^b^               166.2±73.56        249.5±124.1    0.007\*
  Hemoglobin^b^        129.1±22.2         118.7±26.87    0.23

^a^median with range; p value was calculated by Mann-Whitney-U test; ^b^mean ± standard deviation; differences between groups were analyzed by Student's t-test; NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; \*p value lower than 0.05 set as the level of significance

###### Age, complete blood count and disease-free survival in the study population

  Characteristic       Disease-free survival   p value       
  -------------------- ----------------------- ------------- ----------
  Yes                  No                                    
  Number of patients   50                      21            \-
  Age^a^ (yrs)         61 (36-79)              59 (34-79)    0.29
  Leukocytes^b^        7.93±1.92               9.05±2.48     0.04\*
  Neutrophils^b^       4.86±1.44               4.79±2.19     0.0014\*
  Lymphocytes^b^       2.07±0.58               1.8±0.54      0.08
  Platelets^b^         294.9±85.7              380.9±169.9   0.006\*
  NLR^b^               2.56±1.17               3.84±1.75     0.0006\*
  PLR^b^               155.6±70.04             223.1±96.18   0.0015\*
  Hemoglobin^b^        131.7±21.6              118.8±23.49   0.028\*

^a^median with range; p value was calculated by Mann-Whitney-U test; ^b^mean ± standard deviation; differences between groups were analyzed by Student's t-test; NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; \*p value lower than 0.05 set as the level of significance

###### Univariate analysis of age, sex, adjuvant chemo-radiotherapy, tumor stage, NLR, PLR and platelets in the study population

  ---------------------------------------------------------------------------------------------------------------
  Patient characteristic    Overall survival   Disease-free survival                                   
  ------------------------- ------------------ ----------------------- --------- -------- ------------ ----------
  HR                        95% CI             p-value                 HR        95% CI   p-value      

  Age^a^ (yrs):\            1.09               0.27-4.4                0.89      0.94     0.39-2.22    0.89
    \<60\                                                                                              
    \>60                                                                                               

  Sex:\                     2.03               0.46-8.29               0.36      1.26     0.5-3.12     0.63
    female\                                                                                            
    male                                                                                               

  Adjuvant chemotherapy:\   0.64               0.15-2.64               0.54      1.93     0.78-4.46    0.16
    no\                                                                                                
    yes                                                                                                

  Stage\                    2.89               0.22-169                0.29      1.42     0.28-8.31    0.63
    3\                                                                                                 
    4                                                                                                  

  NLR\                      4.75               1.4-33.83               0.017\*   4.38     2.49-19.24   0.0002\*
    \<3.27\                                                                                            
    \>3.27                                                                                             

  Platelets\                1.12               0.28-4.54               0.87      1.64     0.69-3.9     0.26
    \<300\                                                                                             
    \>300                                                                                              

  PLR\                      2.05               0.47-8                  0.36      2.41     0.97-5.39    0.059
    \<150\                                                                                             
    \>150                                                                                              
  ---------------------------------------------------------------------------------------------------------------

NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; HR = hazard ratio; 95% CI = 95% confidence interval; \*p value lower than 0.05 set as the level of significance

###### Multivariate analysis of adjuvant chemo-radiotherapy, tumor stage, NLR, PLR, platelets and ypTNM in the study population

  ----------------------------------------------------------------------------------------------------------------------
  Patient characteristic    Overall survival   Disease-free survival                                        
  ------------------------- ------------------ ----------------------- -------------- -------- ------------ ------------
  Exp(b)                    95% CI             p-value                 Exp(b)         95% CI   p-value      

  Adjuvant chemotherapy:\                                                             1.92     0.68-5.43    0.22
    no\                                                                                                     
    yes                                                                                                     

  Stage:\                   1.89               0.21-17                 0.57                                 
    3\                                                                                                      
    4                                                                                                       

  NLR:\                     4.22               0.99-17.97              [0.053]{.ul}   3.49     1.19-10.24   0.024\*
    \<3.27\                                                                                                 
    \>3.27                                                                                                  

  Platelets:\                                                                         0.62     0.22-1.72    0.36
    \<300\                                                                                                  
    \>300                                                                                                   

  PLR:\                                                                               2.14     0.61-7.56    0.24
    \<150\                                                                                                  
    \>150                                                                                                   

  ypTNM staging:\           5.02               0.6-41.6                0.14           10.66    2.3-49.49    \<0.0026\*
    ypT0-2 N0\                                                                                              
    ypT3-4/N+                                                                                               
  ----------------------------------------------------------------------------------------------------------------------

NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; Exp(b) = exponential; 95% CI = 95% confidence interval; \*p value lower than 0.05 set as the level of significance

Discussion
==========

Some studies demonstrated that preoperative NLR and PLR were significantly increased in CRC patients when compared to healthy controls. Furthermore, some authors suggest that NLR might be a useful, simple and inexpensive biomarker of response to CRT in patients with CRC ([@r3], [@r4]). Malietzis *et al*. ([@r6]) analyzed 13 studies which evaluated NLR as a sign of treatment outcome in patients with CRC. They report that a high pre-treatment NLR independently predicted shorter survival in all studies (HR 2.08; 95% CI 1.64-2.64) ([@r6]). Furthermore, high NLR became a significant sign of poor outcome at years 2 and 3, but not in the first year of follow up. Furthermore, He *et al*. ([@r7]) conclude that NLR and CRP were the only independent factors for OS and progression-free survival (PFS) in CRC patients. Additionally, Li *et al*. ([@r3]) analyzed data from 16 studies in order to associate NLR with OS and PFS in CRC patients. Their analysis revealed that elevated pretreatment NLR correlated with poorer OS and PFS in CRC patients. Increased NLR significantly correlated with lower tumor differentiation and higher carcinoembryonic antigen level ([@r3]). Galizia *et al*. ([@r8]) report that decreased NLR values correlated significantly with increased DFS; along with increased carcinoembryonic antigen levels and Dukes B stage, increased levels of NLR independently depicted worse prognosis in 503 CRC patients. This finding is in concordance with our results. Even in Dukes A patients, NLR differentiated between relapsing and non-relapsing patients. Preoperative NLR as an inexpensive and easily available biomarker might indicate tumor recurrence and should be implemented in tailored therapy in early stage of CRC. Onozawa *et al*. ([@r9]) analyzed 83 patients administered oxaliplatin-based chemotherapy for stage IV CRC, divided into two groups according to NLR; the median survival time of patients with high NLR (≥3.0) was significantly worse than that of patients with low NLR (\<3.0; 16.1 months *vs*. 25.4 months, p=0.03). Ying *et al*. ([@r10]) studied preoperative NLR, PLR and lymphocyte-to-monocyte ratio in 205 surgical CRC patients. They concluded that preoperatively elevated NLR was an independent prognostic marker for recurrent-free survival, OS and cancer specific survival ([@r10]). However, Shen *et al*. ([@r11]) report no significant correlation between NLR and response to neoadjuvant CRT. Nevertheless, the same authors conclude that an increased baseline NLR is a simple, inexpensive and available prognostic marker for OS together with tumor response after neoadjuvant therapy ([@r11]). All these findings are in concordance with our results as well. Giakoustidis *et al*. ([@r12]) analyzed 169 CRC patients that underwent neoadjuvant CRT; 42% of the study patients had increased NLR \>2.5, which correlated with shorter OS but not with DFS. This finding is partially concordant with our results.

Kim *et al*. ([@r13]) report that patients with pre-treatment thrombocytosis had decreased 3-year DFS and OS when compared with patients with normal pre-treatment platelet counts. Therefore, the same authors conclude that thrombocytosis is a negative indicator in these patients, which points to shorter survival in patients with CRC ([@r13]). Wei *et al*. ([@r14]) showed that the baseline platelet count correlated with recurrence in 286 patients with stage II-III CRC receiving adjuvant chemotherapy. The optimal cut-off affecting recurrence was 276×10^9^/L. Kaplan-Meier showed that those with baseline platelet count \>276×10^9^/L receiving adjuvant chemotherapy had worse DFS than those with baseline platelet count ≤276×10^9^/L, with 5-year DFS 66% and 80%, respectively. At the end, CRC patients receiving adjuvant chemotherapy with baseline platelet count \>276×10^9^/L had worse prognosis ([@r14]). The same correlation between thrombocytosis and DFS but not OS was recorded in our patients.

The results of this study showed that, irrespective of the statistical method employed (except for multivariate analysis), NLR was a significant predictor of DFS and OS. It may be that the patient follow up period was too short, so the results of multivariate analysis did not reach significance regarding NLR and OS (patients were recruited from the 2011-2015 period). However, the results almost reached significance (p=0.053).

The neutrophil-to-lymphocyte ratio is not a predictor of pathological response to neoadjuvant CRT, i.e. be the NLR high or low, we could not conclude whether the patient would have better or worse response to neoadjuvant CRT, which is consistent with other authors. However, the results of univariate analysis showed significant correlation of advanced pathological TNM stage with both DFS and OS.
